{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:18:22Z","timestamp":1780049902115,"version":"3.53.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-025-00421-7","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T11:24:27Z","timestamp":1764069867000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7371-5742","authenticated-orcid":false,"given":"Joshua D.","family":"Mitchell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6472-7896","authenticated-orcid":false,"given":"Michael","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Boehmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gorcsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6436-8110","authenticated-orcid":false,"given":"Shunsuke","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7438-8250","authenticated-orcid":false,"given":"Yoshiyuki","family":"Orihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalina","family":"Dronamraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Dhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0242-6449","authenticated-orcid":false,"given":"Tara L.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey L.","family":"Uy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Lancet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"6","key":"421_CR1","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1182\/blood.V58.6.1203.1203","volume":"58","author":"KR Rai","year":"1981","unstructured":"Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981;58(6):1203\u201312.","journal-title":"Blood"},{"issue":"2","key":"421_CR2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1182\/blood.V60.2.454.454","volume":"60","author":"J Yates","year":"1982","unstructured":"Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with Daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982;60(2):454\u201362.","journal-title":"Blood"},{"issue":"1","key":"421_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","volume":"127","author":"H Dombret","year":"2016","unstructured":"Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53\u201361.","journal-title":"Blood"},{"issue":"4","key":"421_CR4","first-page":"485","volume":"57","author":"JW Yates","year":"1973","unstructured":"Yates JW, Wallace HJ Jr., Ellison RR, et al. Cytosine arabinoside (NSC-63878) and Daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57(4):485\u20138.","journal-title":"Cancer Chemother Rep"},{"issue":"1","key":"421_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3324\/haematol.2021.280161","volume":"107","author":"JM Rowe","year":"2022","unstructured":"Rowe JM. The 7\u2009+\u20093 regimen in acute myeloid leukemia. Haematologica. 2022;107(1):3.","journal-title":"Haematologica"},{"issue":"1","key":"421_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/hematology.2022000324","volume":"2022","author":"A Matthews","year":"2022","unstructured":"Matthews A, Pratz KW. Optimizing outcomes in secondary AML. Hematology. 2022;2022(1):23\u20139.","journal-title":"Hematology"},{"issue":"Supplement_1","key":"421_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2019-127356","volume":"134","author":"M Othus","year":"2019","unstructured":"Othus M, Garcia-Manero G, Godwin JE, et al. Increasing lengths of first complete remission with 7\u2009+\u20093 induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data. Blood. 2019;134(Supplement_1):291.","journal-title":"Blood"},{"issue":"1","key":"421_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3324\/haematol.2022.280765","volume":"108","author":"M Othus","year":"2023","unstructured":"Othus M, Garcia-Manero G, Godwin JE, et al. Improved outcomes with 7\u2009+\u20093 induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data. Haematologica. 2023;108(1):42\u20137.","journal-title":"Haematologica"},{"issue":"2","key":"421_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2):41.","journal-title":"Blood Cancer J"},{"key":"421_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","volume":"7","author":"D Cardinale","year":"2020","unstructured":"Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020;7:26.","journal-title":"Front Cardiovasc Med"},{"key":"421_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1200\/EDBK_100015","volume":"38","author":"S Armenian","year":"2018","unstructured":"Armenian S, Bhatia S. Predicting and preventing anthracycline-related cardiotoxicity. Am Soc Clin Oncol Educ Book. 2018;38:3\u201312.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"421_CR12","first-page":"15","volume":"11","author":"F Cai","year":"2019","unstructured":"Cai F, Luis MAF, Lin X, et al. Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: preventive strategies and treatment. Mol Clin Oncol. 2019;11(1):15\u201323.","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"421_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/cts.12857","volume":"14","author":"M Tantawy","year":"2021","unstructured":"Tantawy M, Pamittan FG, Singh S, et al. Epigenetic changes associated with anthracycline-induced cardiotoxicity. Clin Transl Sci. 2021;14(1):36\u201346.","journal-title":"Clin Transl Sci"},{"issue":"2","key":"421_CR14","first-page":"208","volume":"1","author":"Y Kang","year":"2019","unstructured":"Kang Y, Assuncao BL, Denduluri S, et al. Symptomatic heart failure in acute leukemia patients treated with anthracyclines. JACC: CardioOncology. 2019;1(2):208\u201317.","journal-title":"JACC: CardioOncology"},{"issue":"8","key":"421_CR15","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35(8):893\u2013911.","journal-title":"J Clin Oncol"},{"issue":"1","key":"421_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-017-0034-x","volume":"1","author":"X Han","year":"2017","unstructured":"Han X, Zhou Y, Liu W. Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy. NPJ Precis Oncol. 2017;1(1):31.","journal-title":"NPJ Precis Oncol"},{"issue":"9","key":"421_CR17","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","volume":"27","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911\u201339.","journal-title":"J Am Soc Echocardiogr"},{"issue":"29","key":"421_CR18","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1200\/JCO.2013.49.3205","volume":"31","author":"GT Armstrong","year":"2013","unstructured":"Armstrong GT, Oeffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013;31(29):3673\u201380.","journal-title":"J Clin Oncol"},{"issue":"10","key":"421_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41408-020-00376-1","volume":"10","author":"N Daver","year":"2020","unstructured":"Daver N, Wei AH, Pollyea DA, et al. New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J. 2020;10(10):107.","journal-title":"Blood Cancer J"},{"issue":"2","key":"421_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5742\/MEIM.2017.92935","volume":"10","author":"A Elyamany","year":"2017","unstructured":"Elyamany A, Abdel-Aziz NM, Khaled SA, et al. Anthracycline versus non-anthracycline induction regimens in patients with de Novo acute myeloid leukemia. Middle East J Intern Med. 2017;10(2):3\u201311.","journal-title":"Middle East J Intern Med"},{"issue":"41","key":"421_CR21","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, Lopez-Fernandez T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"issue":"2","key":"421_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171\u201390.","journal-title":"Ann Oncol"},{"key":"421_CR23","volume-title":"And cytarabine) liposome for injection, for intravenous use [prescribing information]","author":"VYXEOS\u00ae (daunorubincin","year":"2022","unstructured":"VYXEOS\u00ae (daunorubincin. And cytarabine) liposome for injection, for intravenous use [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; 2022."},{"key":"421_CR24","volume-title":"And cytarabine liposome for injection) product monograph","author":"VYXEOS\u00ae (daunorubicin","year":"2023","unstructured":"VYXEOS\u00ae (daunorubicin. And cytarabine liposome for injection) product monograph. Mississauga, ON: Jazz Pharmaceuticals Canada, Inc.; 2023."},{"key":"421_CR25","volume-title":"44 Mg\/100 Mg powder for concentrate for solution for infusion) summary of product characteristics","author":"Vyxeos liposomal","year":"2024","unstructured":"Vyxeos liposomal. 44\u00a0mg\/100\u00a0mg powder for concentrate for solution for infusion) summary of product characteristics. European Medicines Agency: Jazz Pharmaceuticals Ireland, Ltd.; 2024."},{"key":"421_CR26","volume-title":"44 Mg\/100 Mg powder for concentrate for solution for infusion) summary of product characteristics","author":"Vyxeos liposomal","year":"2025","unstructured":"Vyxeos liposomal. 44\u00a0mg\/100\u00a0mg powder for concentrate for solution for infusion) summary of product characteristics. Electronic Medicines Compendium: Jazz Pharmaceuticals UK, Ltd.; 2025."},{"issue":"26","key":"421_CR27","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684\u201392.","journal-title":"J Clin Oncol"},{"issue":"7","key":"421_CR28","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","volume":"8","author":"JE Lancet","year":"2021","unstructured":"Lancet JE, Uy GL, Newell LF, et al. CPX-351 versus 7\u2009+\u20093 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8(7):e481\u201391.","journal-title":"Lancet Haematol"},{"key":"421_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2020.102275","volume":"30","author":"Q Wang","year":"2020","unstructured":"Wang Q, Tardi P, Sadowski N, et al. Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals. Nanomedicine. 2020;30:102275.","journal-title":"Nanomedicine"},{"issue":"1","key":"421_CR30","doi-asserted-by":"publisher","first-page":"21054","DOI":"10.1038\/s41598-023-47293-4","volume":"13","author":"MC Fortin","year":"2023","unstructured":"Fortin MC, LaCroix AS, Grammatopoulos TN, et al. Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro. Sci Rep. 2023;13(1):21054.","journal-title":"Sci Rep"},{"issue":"5","key":"421_CR31","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937\u201351.","journal-title":"Blood"},{"issue":"12","key":"421_CR32","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1080\/14779072.2016.1239528","volume":"14","author":"D Cardinale","year":"2016","unstructured":"Cardinale D, Cipolla CM. Chemotherapy-induced cardiotoxicity: importance of early detection. Expert Rev Cardiovasc Ther. 2016;14(12):1297\u20139.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"4","key":"421_CR33","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","volume":"77","author":"P Thavendiranathan","year":"2021","unstructured":"Thavendiranathan P, Negishi T, Somerset E, et al. Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol. 2021;77(4):392\u2013401.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"421_CR34","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","volume":"4","author":"EK Oikonomou","year":"2019","unstructured":"Oikonomou EK, Kokkinidis DG, Kampaktsis PN, et al. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiol. 2019;4(10):1007\u201318.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"421_CR35","first-page":"1","volume":"3","author":"R Dobson","year":"2021","unstructured":"Dobson R, Ghosh AK, Ky B, et al. BSE and BCOS guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and\/or trastuzumab. JACC: CardioOncology. 2021;3(1):1\u201316.","journal-title":"JACC: CardioOncology"},{"issue":"8","key":"421_CR36","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.jcmg.2018.03.019","volume":"11","author":"T Negishi","year":"2018","unstructured":"Negishi T, Thavendiranathan P, Negishi K, et al. Rationale and design of the strain surveillance of chemotherapy for improving cardiovascular outcomes: the SUCCOUR trial. JACC Cardiovasc Imaging. 2018;11(8):1098\u2013105.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"421_CR37","doi-asserted-by":"publisher","first-page":"e15226","DOI":"10.1016\/j.heliyon.2023.e15226","volume":"9","author":"MT Cannizzaro","year":"2023","unstructured":"Cannizzaro MT, Inserra MC, Passaniti G, et al. Role of advanced cardiovascular imaging in chemotherapy-induced cardiotoxicity. Heliyon. 2023;9(4):e15226.","journal-title":"Heliyon"},{"issue":"6","key":"421_CR38","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jacc.2019.11.059","volume":"75","author":"JM Bonsu","year":"2020","unstructured":"Bonsu JM, Guha A, Charles L, et al. Reporting of cardiovascular events in clinical trials supporting FDA approval of contemporary cancer therapies. J Am Coll Cardiol. 2020;75(6):620\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"421_CR39","first-page":"567","volume":"2","author":"AM Rahman","year":"2007","unstructured":"Rahman AM, Yusuf SW, Ewer MS. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomed. 2007;2(4):567\u201383.","journal-title":"Int J Nanomed"},{"issue":"16","key":"421_CR40","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1016\/j.ejca.2015.07.031","volume":"51","author":"N Yamaguchi","year":"2015","unstructured":"Yamaguchi N, Fujii T, Aoi S, et al. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis. Eur J Cancer. 2015;51(16):2314\u201320.","journal-title":"Eur J Cancer"},{"key":"421_CR41","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/1471-2407-10-337","volume":"10","author":"LA Smith","year":"2010","unstructured":"Smith LA, Cornelius VR, Plummer GL, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337.","journal-title":"BMC Cancer"},{"issue":"9","key":"421_CR42","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.leukres.2010.01.015","volume":"34","author":"WS Lim","year":"2010","unstructured":"Lim WS, Tardi PG, Dos Santos N, et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res. 2010;34(9):1214\u201323.","journal-title":"Leuk Res"}],"updated-by":[{"DOI":"10.1186\/s40959-026-00502-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000}}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00421-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-025-00421-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00421-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T07:02:07Z","timestamp":1779519727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40959-025-00421-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["421"],"URL":"https:\/\/doi.org\/10.1186\/s40959-025-00421-7","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article was revised: the terms \"CPX 351\" and \"follow-up\" are incorrectly displayed as \"CPX351\" and \"follow up\" online in the legends for Figures 1 and 2. Additionally, the \"<\" symbol for \"<18%\" in footnote d of the Figure 1 legend is missing.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40959-026-00502-1","URL":"https:\/\/doi.org\/10.1186\/s40959-026-00502-1","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent were obtained for the phase III trial. This is a post hoc analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JDM has received consulting fees from Alnylam, Altathera, AstraZeneca, Bridgebio, Pfizer, and Race Oncology; and research funding from Myocardial Solutions and Abbott Laboratories. MP has received consulting\/advisory fees from Ancora Heart, speakers\u2019 bureau fees from Abbott Laboratories, and institutional research funding from BioVentrix. JG has received institutional research funding from Jazz Pharmaceuticals. ND was an employee of and held stock ownership\/options in Jazz Pharmaceuticals during manuscript development. SD is an employee of and holds stock ownership\/options in Jazz Pharmaceuticals. SF is an employee of and holds stock ownership\/options in Jazz Pharmaceuticals; and has received honoraria and travel or accommodation expenses from Jazz Pharmaceuticals. TLL has received institutional research funding from Aptevo Therapeutics, Astellas Pharma, BioPath Holdings Inc, Celyad, CicloMed, Cleave Therapeutics, and Jazz Pharmaceuticals, and has served as a consultant for Servier and Jazz Pharmaceuticals. GLU has received consulting\/advisory fees from Jazz Pharmaceuticals and Novartis. JEL has received consulting\/advisory fees from Bristol Myers Squibb, Prelude Therapeutics, and Treadwell Therapeutics; and a member of their immediate family has stock ownership\/options in Arvinas. JEC has received consulting\/advisory fees from BioPath Holdings Inc, Bristol Myers Squibb, Centessa Pharmaceuticals, Gilead Sciences, Menarini, Novartis, Pfizer, and Takeda; and institutional research funding from AbbVie\/Genentech, Actuate Therapeutics, Astellas Pharma, BioPath Holdings Inc, Bristol Myers Squibb, Jazz Pharmaceuticals, Novartis, Pfizer, Sellas Life Sciences, Sun Pharma, and Takeda. The remaining authors have no relationships to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}